Is ABS-301 at ABCSI our drug? It’s not disclosed
Post# of 155627
Watching the presentation now interesting.
“Stegmann also explained how Absci's reverse immunology technology elucidated a potentially novel mechanism of tumor immune evasion in conjunction with the development of ABS-301, which has broad first-in-class potential in immuno-oncology. Stegmann said that several other undisclosed assets are in the target evaluation stage. Find a recording of his full presentation here.”


CytoDyn Inc (CYDY) Stock Research Links
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com